Sign up
Pharma Capital

Optibiotix signs 'very good' manufacturing deal with Tata Chemicals

Stephen O'Hara, chief executive of OptiBiotix Health plc (LON:OPTI) tells Proactive's Andrew Scott they've signed a manufacturing agreement with India-listed food ingredients giant Tata Chemicals.

It is an expansion of a deal the two inked last December and gives Tata, part of the Tata Group, the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain.

 

View full OPTI profile

OptiBiotix Health plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.